首页 / 院系成果 / 成果详情页

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China 期刊论文

编号：

1b142238-bd59-4444-9431-90c344eba045
作者：

Xing, Puyuan^[1,2] Zhu, Yixiang^[1,2] Shan, Ling^[3] Chen, Sipeng^[4] Hao, Xuezhi^[1,2] Li, Junling^[1,2]
语种：

English
期刊：

ONCOTARGET ISSN：1949-2553 2017 年 8 卷 50 期 (87442 - 87454) ; OCT 20
收录：
关键词：

advanced non-small cell lung cancer (NSCLC) multiple treatments taxane nanoparticle albumin bound paclitaxel (Nab-PTX) secreted protein acidic and rich in cysteine (SPARC)
摘要：

For patients with pretreated advanced non-small cell lung cancer (NSCLC), more effective treatments are unmet. We conducted a study to explore the optimal treatment schedule of nanoparticle albumin bound paclitaxel (Nab-PTX) as a second line or later treatment for advanced NSCLC patients in China. Ninety-eight patients, who had experienced failure of prior treatment and received Nab-PTX monotherapy (130 mg/m(2)) on days 1, 8 of a 21-day cycle were included. The median progressionfree survival (PFS) and overall survival (OS) were 4.34 months (95% confidence interval [CI] 3.508 to 5.165 months) and 11.73 months (95% CI 9.211 to 14.247 months), respectively. The objective responses rate (ORR) and disease control rate (DCR) were 22.4% and 74.5%. Prior treatment with taxane and line of therapy did not influence the efficacy of Nab-PTX. The main grade 3 to 4 toxicities were neutropenia (25.5%) and leukopenia (12.4%). Furthermore, 24 cases offered samples to assess secreted protein acidic and rich in cysteine (SPARC) expression. No statistical difference was observed in treatment efficacy between SPARC expression-negative and positive. The findings suggest that weekly Nab-PTX monotherapy is effective and well tolerated for patients with pretreated advanced NSCLC, regardless of prior taxane exposure or line of therapy.
推荐引用方式
GB/T 7714：

Xing Puyuan,Zhu Yixiang,Shan Ling, et al. The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China [J].ONCOTARGET,2017,8(50):87442-87454.
APA：

Xing Puyuan,Zhu Yixiang,Shan Ling,Chen Sipeng,&Li Junling.(2017).The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China .ONCOTARGET,8(50):87442-87454.
MLA：

Xing Puyuan, et al. "The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China" .ONCOTARGET 8,50(2017):87442-87454.

浏览次数：4  下载次数：0

分享到：

浏览次数：4

下载次数：0

打印次数：0